Cidara Therapeutics jumps after accelerating late-stage trial for influenza therapy

ReutersSep 24, 2025 4:29 PM

View all comments（0）



Shares of drugmaker Cidara Therapeutics CDTX.O rise 17.9% to over a 5-year high of $87.25

Company says it has accelerated the late-stage study of its experimental influenza therapy, CD388, by six months

Following FDA feedback, the study will now include healthy adults over 65, along with people over 12 years of age who have high-risk conditions or weakened immune system - CDTX

In the late-stage trial, the company will test the safety and effectiveness of a single 450 mg dose of CD388, given as a shot under the skin at the start of flu season

RBC expects CD388 to move quickly through development and believes it could generate around $3.7 billion in global sales in the future

RBC added that the FDA indicated one Phase III trial would be sufficient to support the application, with data from the earlier Phase IIb trial aiding the process, alleviating concerns some investors had about potential delays

Including session moves, stock has more than tripled YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Kospi Plunges Over 5% After Nearing 8,000 Points as South Korean Top Official Proposes ‘AI Profit Redistribution’

Tradingkey - During the early trading session on May 12, the KOSPI Index briefly touched the 8,000-point mark at the open before plunging more than 5% to a low of 7,421.71 points. As of press time, the index remains down 1.24% at 7,725.33 points. Samsung Electronics and SK Hynix, which together account for nearly half of the KOSPI's total market capitalization, were the primary drivers of this flash crash. Currently, SK Hynix is down 3.62% at 1.144 million KRW, while Samsung Electronics has fallen 2.28% to 279,000 KRW.

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

TradingKey - Despite the ongoing US-Iran war and the continued closure of the Strait of Hormuz, copper prices maintain a solid floor. This Monday, LME (London Metal Exchange) three-month copper reached $13,637 per tonne at one point, marking its highest level since January 29. On the same day, LME three-month copper recorded a peak closing price of $13,952/tonne, with intraday prices briefly rising above $14,500/tonne.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

TradingKey - The U.S. Bureau of Labor Statistics will release the April CPI report on May 12 at 8:30 a.m. ET. Since the outbreak of the U.S.-Iran conflict in late February, the global energy market has experienced the most severe geopolitical supply shock in history. As the conflict enters its third month, traffic through the Strait of Hormuz remains significantly below pre-war levels, with approximately 20% of the world's oil transit routes still facing "interruption." This inflation report will serve as a critical validation window for the transmission effects of oil prices.

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

TradingKey — As the Nasdaq continues to hit consecutive record highs, Michael Burry—who rose to fame during the 2008 subprime mortgage crisis and was the inspiration for the film *The Big Short*—is betting with unprecedented intensity on the bursting of the AI bubble.

Featured Tools